Richmond, Virginia-based Qnovia develops the RespiRx drug delivery platform that leverages a vibrating mesh nebulizer. CEO Brian Quigley explained the technology to Drug Delivery Business News last year.
The company designed the QN-01 therapy to meet the need for safe and effective pharmacotherapies that address the shortcomings of currently available nicotine replacement therapies (NRTs). According to the company, existing pharmacotherapies lack the rapid onset and peak levels of nicotine delivery. They fail to effectively alleviate cravings and withdrawal symptoms during a quit attempt.